Assistant Staff
Email: sauttog@ccf.org
Location:
Cleveland Clinic Florida Research & Innovation Center
Dr. Sautto has focused his research activity on the selection, cloning, characterization and engineering of monoclonal antibodies (mAbs) of human and animal origin, and directed against infectious agents (such as HCV, influenza virus and opportunistic fungi). In particular, he investigates the potential of these mAbs not only as possible therapeutic drugs, able to directly neutralize infectious pathogens but also as indirect molecules to be exploited for the development of prophylactic approaches. Moreover, their possible engineering in order to improve (i.e., their binding or stability characteristics) or gain new functions (such as in the case of chimeric antigen receptors, CARs), represents a promising and alternative approach for difficult-to-eradicate infectious pathogens explored by his lab.
Learn more on the Research tab.
Dr. Sautto obtained his Bachelor’s degree in Medical Biotechnology at the University of Milan (Italy) in 2006. He then received a Master’s Degree in Molecular and Cellular Medical Biotechnology in 2008, and a PhD in Molecular Medicine in 2012 at the Vita-Salute San Raffaele University of Milan.He gave also lectures on Microbiology and Virology to undergraduate and graduate students as adjunct professor.
He joined as a visiting scientist the International Novartis BioCamp in Basel (Switzerland) in 2012, the Institut de Biologie Structurale in Grenoble (France) in 2013, the Institute of Virology of the Technical University of Munich (Germany) in 2014. In 2016 he moved to the US at the Center for Vaccines and Immunology of the University of Georgia, where he expanded is area of investigation to the development and characterization of next-generation vaccines. During this period at the University of Georgia, he also completed the MBA program of the Terry College of Business. Through the training funds he was awarded, he also had the opportunity to join as a visiting scientist the Vanderbilt University Medical Center and the University of Texas at Austin.
He is author, editor and reviewer of several international scientific journals. In 2015 he was awarded by the Carlo Erba Foundation for his research activity on viral diseases.
Dr. Sautto has focused his research activity on the selection, cloning, characterization and engineering of monoclonal antibodies (mAbs) of human and animal origin, and directed against infectious agents (such as HCV, influenza virus and opportunistic fungi). In particular, he investigates the potential of these mAbs not only as possible therapeutic drugs, able to directly neutralize infectious pathogens but also as indirect molecules to be exploited for the development of prophylactic approaches. Moreover, their possible engineering in order to improve (i.e., their binding or stability characteristics) or gain new functions (such as in the case of chimeric antigen receptors, CARs), represents a promising and alternative approach for difficult-to-eradicate infectious pathogens explored by his lab.
View publications for Giuseppe Sautto, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)